AE	Adverse Event
ANC	Absolute Neutrophil Count
CISH	Chromogenic In Situ Hybridisation
CMV	Cytomegalovirus
CT	Computed Tomography
ctDNA	Circulating Tumour DNA
CYP3A4	Cytochrome P450 3A4
ddPCR	Droplet Digital PCR
DLT	Dose Limiting Toxicity
DNA	Deoxyribonucleic Acid
ECOG	Eastern Cooperative Oncology Group
FFPE	Formalin Fixed Paraffin Embedded
FISH	Fluorescence In Situ Hybridisation
GCP	Good Clinical Practice
HER2	Human Epidermal Growth Factor Receptor 2
HIV	Human Immunodeficiency Virus
HPRA	Health Products Regulatory Authority of Ireland
IHC	Immunohistochemistry
IV	Intravenous
MTD	Maximum Tolerated Dose
NGS	Next Generation Sequencing
PI3K	Phosphoinositide-3 Kinase
RECIST	Response Evaluation Criteria in Solid Tumours
SAE	Serious Adverse Event
T-DM1	Trastuzumab Emtansine
WES	Whole Exome Sequencing
WT	Wildtype
VAF	Variant Allele Frequency